Univariable analysis of effect of molecular-genetic features on survival
| Factor . | HR . | 95% CI . | P . |
|---|---|---|---|
| Cytogenetic risk* | |||
| Low | Reference | ||
| Intermediate | 0.71 | 0.42-1.18 | .18 |
| High | 1.19 | 0.71-1.97 | .51 |
| Mutation | |||
| TET2 | 1.11 | 0.76-1.61 | .60 |
| ASXL1 | 1.45 | 1.00-2.10 | .05 |
| NRAS | 1.67 | 1.11-2.52 | .01 |
| KRAS | 1.34 | 0.78-2.32 | .29 |
| SETBP1 | 0.91 | 0.55-1.53 | .73 |
| JAK2 | 0.80 | 0.37-1.71 | .56 |
| CBL | 1.08 | 0.62-1.68 | .95 |
| DNMT3A | 0.90 | 0.57-1.44 | .68 |
| EZH2 | 1.09 | 0.62-1.91 | .76 |
| IDH1 | 1.28 | 0.68-2.38 | .44 |
| IDH2 | 0.67 | 0.25-1.83 | .44 |
| ZRSR2 | 0.74 | 0.40-1.38 | .34 |
| U2AF1 | 0.93 | 0.55-1.58 | .79 |
| SH2B3 | 1.09 | 0.48-2.48 | .83 |
| SRSF2 | 1.28 | 0.88-1.86 | .19 |
| ETV6 | 0.75 | 0.18-3.02 | .68 |
| TP53 | 1.31 | 0.70-2.42 | .40 |
| RUNX1 | 1.27 | 0.83-1.95 | .26 |
| SF3B1 | 0.86 | 0.44-1.71 | .68 |
| No. of mutations | |||
| Continuous | 1.09 | 0.98-1.22 | .10 |
| 0-2 | Reference | ||
| >2 | 1.39 | 0.97-2.01 | .08 |
| Genetic risk† | |||
| Low | Reference | ||
| Intermediate-1 | 0.96 | 0.57-1.62 | .88 |
| Intermediate-2 | 1.02 | 0.56-1.85 | .95 |
| High | 1.34 | 0.79-2.27 | .27 |
| Factor . | HR . | 95% CI . | P . |
|---|---|---|---|
| Cytogenetic risk* | |||
| Low | Reference | ||
| Intermediate | 0.71 | 0.42-1.18 | .18 |
| High | 1.19 | 0.71-1.97 | .51 |
| Mutation | |||
| TET2 | 1.11 | 0.76-1.61 | .60 |
| ASXL1 | 1.45 | 1.00-2.10 | .05 |
| NRAS | 1.67 | 1.11-2.52 | .01 |
| KRAS | 1.34 | 0.78-2.32 | .29 |
| SETBP1 | 0.91 | 0.55-1.53 | .73 |
| JAK2 | 0.80 | 0.37-1.71 | .56 |
| CBL | 1.08 | 0.62-1.68 | .95 |
| DNMT3A | 0.90 | 0.57-1.44 | .68 |
| EZH2 | 1.09 | 0.62-1.91 | .76 |
| IDH1 | 1.28 | 0.68-2.38 | .44 |
| IDH2 | 0.67 | 0.25-1.83 | .44 |
| ZRSR2 | 0.74 | 0.40-1.38 | .34 |
| U2AF1 | 0.93 | 0.55-1.58 | .79 |
| SH2B3 | 1.09 | 0.48-2.48 | .83 |
| SRSF2 | 1.28 | 0.88-1.86 | .19 |
| ETV6 | 0.75 | 0.18-3.02 | .68 |
| TP53 | 1.31 | 0.70-2.42 | .40 |
| RUNX1 | 1.27 | 0.83-1.95 | .26 |
| SF3B1 | 0.86 | 0.44-1.71 | .68 |
| No. of mutations | |||
| Continuous | 1.09 | 0.98-1.22 | .10 |
| 0-2 | Reference | ||
| >2 | 1.39 | 0.97-2.01 | .08 |
| Genetic risk† | |||
| Low | Reference | ||
| Intermediate-1 | 0.96 | 0.57-1.62 | .88 |
| Intermediate-2 | 1.02 | 0.56-1.85 | .95 |
| High | 1.34 | 0.79-2.27 | .27 |
As defined in Such et al12 : low, normal and isolated -Y; intermediate, other abnormalities; and high, trisomy 8, complex karyotype (≥3 abnormalities), and abnormalities of chromosome 7.
As defined in Elenea et al15 : cytogenetic risk, presence or absence of ASXL1 and/or NRAS and/or RUNX1 and/or SETBP1 mutations.